TAILORING TREATMENT FOR OVARIAN CANCER

30 March 2023

Fairfax & Roberts is delighted to partner with The Westmead Institute for Medical Research (WIMR) to raise awareness and directly support its pioneering and lifesaving work into some of the most serious disease challenges of our time.

WIMR’s Centre for Cancer Research, led by Professor Anna De Fazio AM, is determined to improve outcomes for the more than 1700 Australian women[1] diagnosed with ovarian cancer each year. Sadly, the 5-year survival-rate for ovarian cancer is still less than 50%.

ONE TREATMENT DOES NOT FIT ALL

One barrier to improving outcomes is that ovarian cancer has, until recently, been treated as a single disease.

Professor De Fazio says, “We now understand that ovarian cancer is a complex, diverse disease. There are several subtypes, and they are considerably different in how they develop, and how they respond to standard treatments.

“The more we learn about the differences between each patient, the more we realise that standard treatments may not always result in the best outcome.”

TAILORING TREATMENT FOR OVARIAN CANCER - Professor Anna De Fazio AM in the WIMR laboratory.

Professor Anna De Fazio AM in the WIMR laboratory.

BESPOKE TREATMENT

Professor De Fazio leads an ovarian cancer research program called INOVATe (Individualised Ovarian Cancer Treatment Through Integration of Genomic Pathology into Multidisciplinary Care).

Professor De Fazio says, “This is a large study that analyses each patient’s tumour in great detail, at a genetic and molecular level, and uses this information to match the patient with the most appropriate clinical trial. The aim is to deliver a more precise treatment, improving outcomes and ultimately, saving lives.”

TAILORING TREATMENT FOR OVARIAN CANCER - Professor Anna De Fazio AM

Professor Anna De Fazio AM

 https://www.ovariancancer.net.au/page/67/about-ovarian-cancer

 

Browse the Taia Collection